# A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer

> **NCT02890511** · PHASE1,PHASE2 · COMPLETED · sponsor: **Daehwa Pharmaceutical Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Solid Tumor
- Stage IV Gastric Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02890511
- **Lead sponsor:** Daehwa Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890511, "A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02890511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*